Clinical trials: Mecamylamine
Nicotine Dependence
Nicotinic Modulation of the Default Network of Resting Brain Function
Background: A brain circuit called the default network is the brain circuit that is active when the brain is at rest; that is, when individuals are not concentrating on specific tasks.
- Trial name
- NCT01240616
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cognition in Schizophrenia
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products.
- Trial name
- NCT00455650
- Testing
- Mecamylamine, Varenicline
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy Subjects
Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214
(Food versus no food) crossover study to measure the effects of food on pharmacokinetics of TC-5214 (S-Mecamylamine) in healthy Subjects.
- Trial name
- TC-5214 (NCT01458899)
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects
The purpose of this study is to assess safety, tolerability and pharmacokinetics after a single and repeated oral doses of TC-5214 (S-mecamylamine) in healthy male Japanese subjects.
- Trial name
- NCT01175564
- Testing
- TC-5214
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
To investigate the safety and tolerability of TC-5214 following oral administration of single and multiple ascending doses compared to placebo.
- Trial name
- NCT01145768
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Magnetic Resonance Imaging, Cognition
Nicotinic Modulation of the Default Network
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed…
- Conditions
- Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
- Trial name
- NCT01223404
- Testing
- Nicotine, Mecamylamine
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Healthy Volunteers, Patients
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
The purpose of this study is to compare the absorption and distribution of a single oral dose of TC-5214 in subjects with renal impairment and with subjects with normal renal function.
- Conditions
- Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
- Trial name
- NCT01240967
- Testing
- TC-5214
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca